BACKGROUND: Quadrivalent meningococcal conjugate vaccine (Menactra [MenACWY-D]), was licensed in the United States in 2005 to prevent meningococcal disease in adolescents and adults. The license was extended to children aged 2-10 years in 2007 and extended again in 2011 to infants aged 9 months and older based, in part, on results from 3 phase III studies presented herein. METHODS: The safety and immunogenicity of 2 doses of MenACWY-D was assessed in study-eligible children: dose 1 was administered at 9 months of age and dose 2 was administered 3 months later with or without routine childhood vaccines. RESULTS: Thirty days after vaccination, protective serum bactericidal assay-human complement titers ≥1:8 for meningococcal serogroups A, C, Y and W-135 were achieved by 86-100% of children receiving 2 doses of MenACWY-D. When MenACWY-D was concomitantly administered with measles, mumps, rubella and varicella or heptavalent pneumococcal conjugate vaccine, 81-98% of participants achieved protective responses (serum bactericidal assay-human complement titers ≥1:8 for all serogroups). All seroprotection rates were >91% when the protective titer was defined as serum bactericidal assay-human complement ≥1:4. MenACWY-D did not interfere with measles, mumps, rubella or varicella vaccine responses (98-100% achieved protective titers). When heptavalent pneumococcal conjugate vaccine was given concomitantly with MenACWY-D, antipneumococcal antibody levels, although decreased, were protective for all serotypes by enzyme-linked immunosorbent assay (98-100% ≥ 0.35 μg/mL) and opsonophagocytic assay (99-100% ≥ 1:8). Adverse events were generally mild and similar across groups. Serious adverse events were uncommon. CONCLUSIONS: MenACWY-D was safe and immunogenic when given in 2 doses to infants and toddlers; this vaccine can be given with other common childhood immunizations.
BACKGROUND: Quadrivalent meningococcal conjugate vaccine (Menactra [MenACWY-D]), was licensed in the United States in 2005 to prevent meningococcal disease in adolescents and adults. The license was extended to children aged 2-10 years in 2007 and extended again in 2011 to infants aged 9 months and older based, in part, on results from 3 phase III studies presented herein. METHODS: The safety and immunogenicity of 2 doses of MenACWY-D was assessed in study-eligible children: dose 1 was administered at 9 months of age and dose 2 was administered 3 months later with or without routine childhood vaccines. RESULTS: Thirty days after vaccination, protective serum bactericidal assay-human complement titers ≥1:8 for meningococcal serogroups A, C, Y and W-135 were achieved by 86-100% of children receiving 2 doses of MenACWY-D. When MenACWY-D was concomitantly administered with measles, mumps, rubella and varicella or heptavalent pneumococcal conjugate vaccine, 81-98% of participants achieved protective responses (serum bactericidal assay-human complement titers ≥1:8 for all serogroups). All seroprotection rates were >91% when the protective titer was defined as serum bactericidal assay-human complement ≥1:4. MenACWY-D did not interfere with measles, mumps, rubella or varicella vaccine responses (98-100% achieved protective titers). When heptavalent pneumococcal conjugate vaccine was given concomitantly with MenACWY-D, antipneumococcal antibody levels, although decreased, were protective for all serotypes by enzyme-linked immunosorbent assay (98-100% ≥ 0.35 μg/mL) and opsonophagocytic assay (99-100% ≥ 1:8). Adverse events were generally mild and similar across groups. Serious adverse events were uncommon. CONCLUSIONS: MenACWY-D was safe and immunogenic when given in 2 doses to infants and toddlers; this vaccine can be given with other common childhood immunizations.
Authors: Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil Journal: MMWR Recomm Rep Date: 2020-09-25
Authors: Francisco Noya; Deirdre McCormack; Donna L Reynolds; Dion Neame; Philipp Oster Journal: Can J Infect Dis Med Microbiol Date: 2014-07 Impact factor: 2.471
Authors: Germán Áñez; James Hedrick; Michael W Simon; Shane Christensen; Robert Jeanfreau; Eddy Yau; Judy Pan; Emilia Jordanov; Mandeep S Dhingra Journal: Hum Vaccin Immunother Date: 2020-03-25 Impact factor: 3.452
Authors: Li Ou; Wing-Pui Kong; Gwo-Yu Chuang; Mridul Ghosh; Krishana Gulla; Sijy O'Dell; Joseph Varriale; Nathan Barefoot; Anita Changela; Cara W Chao; Cheng Cheng; Aliaksandr Druz; Rui Kong; Krisha McKee; Reda Rawi; Edward K Sarfo; Arne Schön; Andrew Shaddeau; Yaroslav Tsybovsky; Raffaello Verardi; Shuishu Wang; Timothy G Wanninger; Kai Xu; Gengcheng J Yang; Baoshan Zhang; Yaqiu Zhang; Tongqing Zhou; Frank J Arnold; Nicole A Doria-Rose; Q Paula Lei; Edward T Ryan; Willie F Vann; John R Mascola; Peter D Kwong Journal: Sci Rep Date: 2020-02-20 Impact factor: 4.996
Authors: Carmen I Baccarini; Michael W Simon; Donald Brandon; Shane Christensen; Emilia Jordanov; Mandeep S Dhingra Journal: Pediatr Infect Dis J Date: 2020-10 Impact factor: 3.806